SEC Comment Letter for NANOBAC PHARMACEUTICALS INC (CIK 0000925894) — Sep 20, 2005
NANOBAC PHARMACEUTICALS INC (CIK 0000925894)
Date: Sept. 20, 2005 · CIK: 0000925894 · Accession: 0000000000-05-048517
AI Filing Summary & Sentiment
Letter
Via Facsimile and U.S. Mail Mail Stop 6010 September 1, 2005 Mr. John Stanton Chief Executive and Financial Officer, and Chairman Nanobac Pharmaceuticals, Inc. 2727 W. Martin Luther King Jr. Boulevard Suite 850 Tampa, FL 33607
Re: Nanobac Pharmaceuticals, Inc. Form 10-KSB/A for the Fiscal Year Ended December 31, 2004 Filed June 17, 2005 File No. 033-80612
Dear Mr. Stanton:
We have completed our review of your Form 10-K and have no further comments at this time.
Sincerely,
Kevin Woody
Branch Chief
Show Raw Text
<DOCUMENT> <TYPE>LETTER <SEQUENCE>1 <FILENAME>filename1.txt <TEXT> Via Facsimile and U.S. Mail Mail Stop 6010 September 1, 2005 Mr. John Stanton Chief Executive and Financial Officer, and Chairman Nanobac Pharmaceuticals, Inc. 2727 W. Martin Luther King Jr. Boulevard Suite 850 Tampa, FL 33607 Re: Nanobac Pharmaceuticals, Inc. Form 10-KSB/A for the Fiscal Year Ended December 31, 2004 Filed June 17, 2005 File No. 033-80612 Dear Mr. Stanton: We have completed our review of your Form 10-K and have no further comments at this time. Sincerely, Kevin Woody Branch Chief ?? ?? ?? ?? Mr. John Stanton Nanobac Pharmaceuticals, Inc. July 8, 2005 Page 1 </TEXT> </DOCUMENT>